Janux Therapeutics is precision engineering novel immunotherapies to fight cancer and autoimmune disease by selectively modulating T cells without causing systemic safety issues.

Check out the drug pipeline for Janux Therapeutics, a clinical-stage biopharmaceutical company developing a broad pipeline of novel T cell immunotherapies.

Jan 26, 2026 · Janux is a clinical-stage company developing precision-engineered immunotherapies that have the potential to generate potent and durable immune responses without causing systemic …

Janux is using its platform masking technology to engineer novel drug candidates that are designed to overcome the traditional TCE toxicity and efficacy limitations. TRACTrs and TRACIrs are …

Jan 22, 2026 · Janux Therapeutics, Inc. (Nasdaq: JANX) (“Janux”), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary …

January 26, 2026 Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer January 22, 2026 Janux Therapeutics Announces Collaboration and Exclusive Worldwide License …

Feb 17, 2026 · Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the first …

Janux Therapeutics is developing a bispecific drug candidate (JANX007) that targets PSMA, a protein expressed in prostate cancer tumors.

Janux is developing novel immunotherapies to stimulate the immune system without causing systemic safety issues to fight cancer and autoimmune diseases.

Feb 26, 2026 · SAN DIEGO-- (BUSINESS WIRE)-- Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, …